Results pending
Epoetin alfa: protect nerve tissue in MS (type not specified)
MS (type not specified) · Axonal protection / ion channels / excitotoxicity
Trials have finished, but some results have not been read yet. There is no verdict until they are, because one unread trial can change the answer.
- Trials
- 1
- Running now
- 0
- Controlled phase 2/3 trials
- 1
- People in controlled trials
- 40
How the verdict was reached
Phase 2 results not all read yet
| Trial | Phase | Participants | Started | Result | Counted |
|---|---|---|---|---|---|
| Vision Protect | Phase 2 | 40 | 2006 | No results found | Will count once its result is read |
Counted: 0. Will count later: 1. Not counted: 0.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- Oct 2026First listed as Results pending
Related hypotheses
- Amiloride: protect nerve tissue in MS (type not specified)
- Epoetin alfa: protect nerve tissue in optic neuritis
- Memantine: protect nerve tissue in MS (type not specified)
- Oxcarbazepine: protect nerve tissue in MS (type not specified)
- Phenytoin: protect nerve tissue in MS (type not specified)
- Gabapentin: repair myelin in MS (type not specified)
- Memantine: repair myelin in MS (type not specified)
- Dronabinol: slow disability worsening in MS (type not specified)
- Levetiracetam: slow disability worsening in MS (type not specified)
- Memantine: slow disability worsening in MS (type not specified)
- Pregabalin: slow disability worsening in MS (type not specified)
- Memantine: reduce relapses and new lesions in MS (type not specified)
Assembled by software from public sources.